close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Pain Relief

The results are compelling: In an analysis of the efficacy of viscosupplements, SYNVISC® provided unsurpassed pain relief.1 In addition, a head-to-head study showed that SYNVISC provided
greater pain relief than Hyalgan®.2

SYNVISC provided unsurpassed pain relief 1

As measured by improvement in the baseline-adjusted sum of pain intensity differences (ASPID) %. ASPID is the baseline-adjusted difference in pain levels for the viscosupplement and placebo groups, summed across time.

The data above was adapted from an independent meta-analysis of 20 blinded, randomized, placebo-controlled HA trials (1,647 knees). A secondary analysis compared 2 pivotal trials of SYNVISC with 15 trials of non-cross-linked HA products. The treatment effect versus placebo was greater for the SYNVISC studies.

The graph below shows that in an independent prospective, randomized, well-controlled trial conducted by Raman et al., SYNVISC provided a faster onset and greater pain relief than Hyalgan®—most notably at 6 and 26 weeks.

SYNVISC provided greater pain relief 2

Prospective, observer-blinded, active-controlled trial of 356 patients with OA knee pain who were randomized to receive either 3 weekly injections of SYNVISC or 5 weekly injections of Hyalgan. Follow-up visits occurred at 6 weeks, 3 months, 6 months, and 1 year. Mean age of patients was 66.7 years. Most had radiographically confirmed Kellgren-Lawrence grade III OA at baseline (SYNVISC 61%; Hyalgan 59%). Pain was measured on a 10-cm visual analog scale (VAS). 2

Hyalgan is a registered trademark of Fidia S.P.A.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)